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LETTERS TO THE EDITOR
Absence of Mutations
in the Epidermal
Growth Factor
Receptor (EGFR) Kinase
Domain in Patients
with Mesothelioma
To the Editor:
Malignant mesothelioma, a debili-
tating and often fatal malignancy occurs
most commonly in patients with a history
of exposure to asbestos. Majority of pa-
tients with pleural malignant mesotheli-
oma present with unresectable disease.
Epidermal Growth Factor Receptor
(EGFR) is one of erbB family of recep-
tor tyrosine kinases (TK) known to play
a critical role in the cell proliferation and
survival in malignant neoplasms. Sev-
eral studies have reported an increased
expression of EGFR in mesothelioma.
EGFR-expressing mesothelioma cell lines
seemed to be sensitive to treatment with
EGFR tyrosine kinase inhibitors.1
After these observations, the Can-
cer and Leukemia Study Group B con-
ducted a phase II trial of gefitinib, an
EGFR TK inhibitor in 43 previously
untreated patients with mesothelioma.2
Of the 28 samples tested for EGFR ex-
pression, 27 (97%) had an overexpres-
sion of EGFR. Despite EGFR overex-
pression, gefitinib was not active in
malignant mesothelioma. EGFR expres-
sion is not an independent prognostic
factor in patients with mesothelioma.2,3
There is a striking discordance between
EGFR expression and lack of response to
EGFR TK inhibitors in malignant me-
sothelioma. Mutations in exons 18–21 of
the EGFR are associated with response
to EGFR TK inhibitors in non-small cell
lung cancer. There are only limited data
on the prevalence of EGFR TK muta-
tions in mesothelioma.
We sought to investigate the pres-
ence of any EGFR mutations in our pa-
tients with mesothelioma. A total of 32
patients with a histologically confirmed
diagnosis of mesothelioma seen at the
Washington University School of Medi-
cine were included in this study. DNA
samples were obtained from paraffin-em-
bedded tissue blocks containing representa-
tive malignant cells. High-throughput (96-
well plate) bidirectional dideoxynucleotide
sequencing of polymerase chain reaction-
amplified gene products was performed at
the Genome Sequencing Center (Wash-
ington University in St. Louis) as per
standard protocol http://genome.wustl.
edu/activity/med_seq/protocols.cgi. Ex-
onic regions 18–21, including the
exon/intron boundaries of EGFR (Entrez
GeneID 2065) were amplified by poly-
merase chain reaction. The sequence
traces were assembled and scanned for
variations from the reference sequence
through the use of PolyPhred and Poly-
Scan. All detailed protocols and primer
sequences are available through the
Washington University School of Medi-
cine GSC website (http://genome.wustl.
edu/platforms.cgi?id7).
After sequencing the DNA from the
32 mesothelioma samples, we found no
evidence of mutations in our set of pa-
tients with mesothelioma. Our findings are
consistent with the three earlier published
studies.3–5 We further confirm the findings
that although increased expression of
EGFR is common in patients with me-
sothelioma, mutations of the EGFR kinase
region commonly occurring in non-small
cell lung cancer seem to be uncommon in
mesothelioma. Lack of activating muta-
tions in the EGFR TK domain may ex-
plain the inactivity of EGFR tyrosine ki-
nase inhibitors in mesothelioma.
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Carboplatin and
Weekly Paclitaxel for
the Treatment of
Advanced Non-small
Cell Lung Cancer
(NSCLC) During
Pregnancy
To the Editor:
Gestational lung cancer is a rare
disease, with less than 40 cases reported
in literature.1 Incidence is rising due to
current trends in delaying pregnancy
and increasing rates of smoking among
young women.2 Here we report a case of
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gestational lung cancer illustrating how
the case was approached and managed.
A 33-year-old nonsmoker preg-
nant woman (19th week) presented with
diminished air entry over the right hemi-
thorax and a 4 cm right axillary lymph
node. Chest ultrasound showed right
sided pleural effusion for which an in-
tercostal tube was inserted and pleu-
rodesis was performed. Magnetic reso-
nance imaging (MRI) showed a right
lung mass (8  5.5 cm) and a medias-
tinal lymph node (6  2 cm). Biopsy
revealed adenocarcinoma grade 3, posi-
tive for TTF-1 and epidermal growth
factor receptor. Brain MRI showed a
solitary brain deposit with surrounding
edema, yet no neurologic symptoms.
MRI abdomen was normal.
The case was discussed in a mul-
tidisciplinary meeting and the patient
was counseled regarding possible treat-
ment options. We explained that admin-
istering chemotherapy during pregnancy
lacks a standardized approach, yet it
could have a palliative role. Neverthe-
less, prognosis remains poor regardless
of pregnancy. We clarified that brain
irradiation could be considered, if neu-
rologic symptoms occurred. Abortion
was also discussed, but the patient
clearly expressed her desire for keeping
the pregnancy, and thus chemotherapy
was started.
The patient was treated with
weekly paclitaxel (60 mg/m2) and car-
boplatin (area under the curve 5) every 3
weeks. The patient received 5 weeks of
chemotherapy with good tolerance and
normal fetal growth. During the 6th
week of therapy, the patient developed
progressive headache for which a cere-
bral MRI showed disease progression,
although chest MRI showed partial re-
sponse. Accordingly, high dose steroids
were given to induce fetal lung matura-
tion and reduce cerebral edema. At the
30th week of pregnancy, a spontaneous
early onset of labor occurred and urgent
cesarean-section was carried out. A
healthy baby boy was delivered with no
evidence of metastasis to the products of
conception. The patient was considered
for brain irradiation but she deteriorated
rapidly and died 4 weeks later. The baby
is now 5-months-old with normal devel-
opment.
Administering chemotherapy dur-
ing pregnancy is potentially toxic but
the risk can be avoided if given after the
first trimester.2 Abortion remains an op-
tion; but it is unknown whether it affects
the maternal prognosis or not. The fam-
ily future should be discussed and re-
specting the patient’s autonomy in such
situations is essential.
Outside pregnancy, chemotherapy
doublet is the standard treatment in ad-
vanced non-small cell lung cancer.3 In
our case, carboplatin and weekly pacli-
taxel was used for the first time during
pregnancy. The weekly application of
paclitaxel allows a lower peak plasma
concentration of the drug resulting in
lower maternal toxicity and possible
lower placental transfer. Our experience
with weekly regimens in gestational
breast cancer has shown high compli-
ance rates with adequate pregnancy
monitoring.4 Carboplatin seems slightly
safer than cisplatin during pregnancy
and hence was favored.5
It is very difficult to generalize
conclusions in such critical clinical sit-
uations. We reinforce on the importance
of performing a thorough counseling
for these patients to reach an informed
decision.
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